IFI27L1: A Potential Drug Target and Biomarker (G122509)
IFI27L1: A Potential Drug Target and Biomarker
Interferon alpha-inducible protein 27-like protein 1 (IFI27L1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. IFI27L1 is a cytoplasmic protein that is expressed in most tissues and cells, and its functions include regulating cell growth, differentiation, and survival. In this article, we will explore the potential implications of IFI27L1 as a drug target and biomarker.
Potential Drug Target
IFI27L1 has been shown to play a critical role in the regulation of cell growth and differentiation, and its dysfunction has been implicated in the development of various diseases. One of the most promising aspects of IFI27L1 is its potential as a drug target. IFI27L1 has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, which is known to play a crucial role in cancer progression and the development of neurodegenerative diseases.
IFI27L1 has also been shown to interact with the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. The TGF-β signaling pathway is known to be involved in the development of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Therefore, IFI27L1 may be a promising drug target for these diseases.
Biomarker
IFI27L1 has also been shown to be a potential biomarker for various diseases. IFI27L1 has been shown to be involved in the regulation of cell growth and differentiation, which may be involved in the development of various diseases. For example, IFI27L1 has been shown to play a role in the regulation of cancer cell growth and has been shown to be involved in the development of various types of cancer.
IFI27L1 has also been shown to be involved in the regulation of autoimmune disorders, including the regulation of T cell development and function. IFI27L1 has been shown to play a role in the regulation of T cell development and has been shown to be involved in the development of autoimmune disorders. Therefore, IFI27L1 may be a potential biomarker for autoimmune disorders.
Conclusion
In conclusion, IFI27L1 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. IFI27L1 has been shown to play a critical role in the regulation of cell growth and differentiation, and its dysfunction has been implicated in the development of various diseases. Therefore, IFI27L1 may be a promising drug target and biomarker for these diseases. Further research is needed to fully understand the role of IFI27L1 as a drug target and biomarker.
Protein Name: Interferon Alpha Inducible Protein 27 Like 1
Functions: Plays a role in the apoptotic process and has a pro-apoptotic activity
More Common Targets
IFI27L2 | IFI30 | IFI35 | IFI44 | IFI44L | IFI6 | IFIH1 | IFIT1 | IFIT1B | IFIT2 | IFIT3 | IFIT5 | IFITM1 | IFITM10 | IFITM2 | IFITM3 | IFITM3P2 | IFITM3P7 | IFITM4P | IFITM5 | IFITM8P | IFITM9P | IFNA1 | IFNA10 | IFNA12P | IFNA13 | IFNA14 | IFNA16 | IFNA17 | IFNA2 | IFNA21 | IFNA22P | IFNA4 | IFNA5 | IFNA6 | IFNA7 | IFNA8 | IFNAR1 | IFNAR2 | IFNB1 | IFNE | IFNG | IFNG-AS1 | IFNGR1 | IFNGR2 | IFNK | IFNL1 | IFNL2 | IFNL3 | IFNL4 | IFNLR1 | IFNW1 | IFNWP15 | IFNWP19 | IFRD1 | IFRD2 | IFT122 | IFT122P3 | IFT140 | IFT172 | IFT20 | IFT22 | IFT27 | IFT43 | IFT46 | IFT52 | IFT57 | IFT74 | IFT80 | IFT81 | IFT88 | IFTAP | IGBP1 | IGBP1P1 | IGDCC3 | IGDCC4 | IgE Receptors | IGF1 | IGF1R | IGF2 | IGF2-AS | IGF2BP1 | IGF2BP2 | IGF2BP2-AS1 | IGF2BP3 | IGF2R | IGFALS | IGFBP-AS1 | IGFBP1 | IGFBP2 | IGFBP3 | IGFBP4 | IGFBP5 | IGFBP6 | IGFBP7 | IGFBP7-AS1 | IGFBPL1 | IGFL1 | IGFL1P2 | IGFL2